RT Journal Article SR Electronic T1 Statin Therapy in Ischemic Stroke Patients with Atrial Fibrillation: Efficacy and Safety Outcomes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.04.19.24306111 DO 10.1101/2024.04.19.24306111 A1 RAF and RAF NOAC-Investigators A1 Marvardi, Michele A1 Ferrante, Mario A1 Paciaroni, Maurizio A1 Abdul-Rahim, Azmil A1 Tsivgoulis, Georgios A1 Seiffge, David Julian A1 Engelter, Stefan T. A1 Lyrer, Philippe A1 Polymeris, Alexandros A. A1 Dittrich, Tolga A1 Cancelloni, Virginia A1 Zietz, Annaelle A1 De Marchis, Gian Marco A1 Putaala, Jukka A1 Strbian, Daniel A1 Tomppo, Liisa A1 Michel, Patrik A1 Strambo, Davide A1 Salerno, Alexander A1 Vanacker, Peter A1 Zuurbier, Susanna A1 Yperzeele, Laetitia A1 Loos, Caroline M.J. A1 Cappellari, Manuel A1 Emiliani, Andrea A1 Zedde, Marialuisa A1 Becattini, Cecilia A1 Pascarella, Rosario A1 Dawson, Jesse A1 Cronshaw, Robert A1 Schirinzi, Erika A1 Del Sette, Massimo A1 Stretz, Christoph A1 Kala, Narendra A1 Schomer, Ashley A1 Mac Grory, Brian A1 Jayaraman, Mahesh A1 Yaghi, Shadi A1 Furie, Karen L. A1 Masotti, Luca A1 Grifoni, Elisa A1 Toni, Danilo A1 Risitano, Angela A1 Falcou, Anne A1 Petraglia, Luca A1 Lotti, Enrico Maria A1 Pavolucci, Lucia A1 Lochner, Piergiorgio A1 Silvestrelli, Giorgio A1 Ciccone, Alfonso A1 Alberti, Andrea A1 Venti, Michele A1 Leone De Magistris, Ilaria A1 Mosconi, Maria Giulia A1 Giustozzi, Michela A1 Kargiotis, Odysseas A1 Rocco, Alessandro A1 Diomedi, Marina A1 Marcheselli, Simona A1 Antonenko, Kateryna A1 Rota, Eugenia A1 Tassinari, Tiziana A1 Saia, Valentina A1 Palmerini, Francesco A1 Aridon, Paolo A1 Arnao, Valentina A1 Monaco, Serena A1 Cottone, Salvatore A1 Baldi, Antonio A1 D’Amore, Cataldo A1 Ageno, Walter A1 Pegoraro, Samuela A1 Ntaios, George A1 Adamou, Anastasia A1 Sagris, Dimitrios A1 Giannopoulos, Sotirios A1 Kosmidou, Maria A1 Ntais, Evangelos A1 Romoli, Michele A1 Pantoni, Leonardo A1 Rosa, Silvia A1 Bertora, Pierluigi A1 Chiti, Alberto A1 Canavero, Isabella A1 Saggese, Carlo Emanuele A1 Plocco, Maurizio A1 Giorli, Elisa A1 Palaiodimou, Lina A1 Bakola, Eleni A1 Bandini, Fabio A1 Gasparro, Antonio A1 Terruso, Valeria A1 Mannino, Marina A1 Pezzini, Alessandro A1 Ornello, Raffaele A1 Sacco, Simona A1 Popovic, Nemanja A1 Scoditti, Umberto A1 Genovese, Antonio A1 Flomin, Yuriy A1 Mancuso, Michelangelo A1 D’Agliano, Roberto A1 Baldini, Marco A1 Ulivi, Leonardo A1 Giannini, Nicola A1 Vadikolias, Kostantinos A1 Liantinioti, Chrysoula A1 Chondrogianni, Maria A1 Halvatsiotis, Panagiotis A1 Karagkiozi, Efstathia A1 Athanasakis, George A1 Makaritsis, Kostantinos A1 Lanari, Alessia A1 Tatlisumak, Turgut A1 Acciarresi, Monica A1 Lorenzini, Gianni A1 Tassi, Rossana A1 Guideri, Francesca A1 Acampa, Maurizio A1 Martini, Giuseppe A1 Sohn, Sung-Il A1 Mumoli, Nicola A1 Carrara, Davide A1 Maccarrone, Miriam A1 Galati, Franco A1 Gourbali, Vanessa A1 Orlandi, Giovanni A1 Giuntini, Martina A1 Corea, Francesco A1 Bellesini, Marta A1 Karapanayiotides, Theodore A1 Csiba, Laszló A1 Szabó, Lilla A1 Imberti, Davide A1 Pieroni, Alessio A1 Barlinn, Kristian A1 Pallesen, Lars-Peder A1 Barlinn, Jessica A1 Doronin, Boris A1 Volodina, Vera A1 Agnelli, Giancarlo A1 Deleu, Dirk A1 Bonetti, Bruno A1 Gentile, Luana A1 Reale, Giuseppe A1 Caliandro, Pietro A1 Morotti, Andrea A1 Vannucchi, Vieri A1 Padroni, Marina A1 Letteri, Federica A1 Magoni, Mauro A1 Tiseo, Cindy A1 Rigatelli, Alberto A1 Zauli, Aurelia A1 Bossi, Francesco A1 Caso, Valeria YR 2024 UL http://medrxiv.org/content/early/2024/04/23/2024.04.19.24306111.abstract AB Background The efficacy and safety of statins for secondary prevention in patients who have experienced a cardioembolic stroke are not well-defined. However, previous observational data reported hyperlipidemia as a risk factor for both ischemic and bleeding complications in patients with AF and previous stroke. Based on these premises, we conducted a sub-analysis of the RAF and RAF-NOAC studies to evaluate the efficacy and safety of statins in secondary prevention in patients with acute ischemic stroke and AF.Methods We combined patient data from the RAF and RAF-NOAC studies, prospective observational studies conducted across Stroke Units in Europe, the United States, and Asia from January 2012 to June 2016. We included consecutive patients with AF who suffered an acute ischemic stroke with a follow-up of 90 days. Our outcomes were the combined endpoint, including stroke, transient ischemic attack, systemic embolism, symptomatic intracerebral hemorrhage, and major extracranial bleeding. Furthermore, both ischemic and hemorrhagic outcomes were evaluated separately.Results A total of 1.742 patients were included (46% male), and 898 (52%) received statins after the index event. At multivariable analysis, statin use was statistically associated with age (OR 0.92, 95% CI 0.97 - 0.99, p = 0.001), male sex (OR 1.35, 95% CI 1.07 - 1.70, p = 0.013), anticoagulation (OR 2.53, 95% CI 1.90 - 3.36, p <0.0001), hyperlipidemia (OR 5.52, 95% CI 4.28 - 7.12, p <0.0001), paroxysmal AF (OR 1.40, 95% CI 1.12 - 1.75, p = 0.003), leukoaraiosis (OR 1.39, 95% CI 1.11 - 1.75, p = 0.004) and heart failure (OR 0.72, 95% CI 0.53 - 0.98, p = 0.034). Statin use was not associated with the combined outcome event (OR 0,81, 95% CI 0,56 – 1,19, p = 0.286) and ischemic outcome event (OR 1,13, 95% CI 0,71 – 1,82, p = 0.604) while was associated with a lower risk of hemorrhagic outcome event (OR 0,49, 95% CI 0,27 – 0,88, p = 0.016).Conclusions Our data show that statins seem to protect against global bleeding events in cardioembolic stroke patients; this may be due to the pleiotropic effect of statins. More data are warranted to confirm these findings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from local Institutional Review Boards as necessary.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that supported the findings of this study are available from the corresponding author upon reasonable request.